Johnson & Johnson (JNJ) FCF Margin (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly FCF Margin came in at 28.82% in Q2 2026, up 1688.0% year-over-year from 1.61% in Q2 2025, and up 373.4% quarter-over-quarter from 6.09% in Q1 2026.
Analysis
Johnson & Johnson (JNJ) FCF Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed FCF Margin across 18 years of filings, most recently posting 28.82% for Q2 2026.
- In Q2 2026, FCF Margin rose 1688.0% year-over-year to 28.82%; the TTM figure through Jun 2026 stood at 22.71% (up 225.0% YoY), while the FY2025 annual figure was 20.91%, down 143.0% from the prior year.
- FCF Margin came in at 28.82% for Q2 2026 at Johnson & Johnson, up from 6.09% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 33.39% in Q3 2025 to a low of 6.09% in Q1 2026.
- Average FCF Margin over 5 years is 19.88%, with a median of 18.87% recorded in 2022.
- Year-over-year, FCF Margin surged 2058 bps in 2023 and plunged 935 bps in 2026.
- Over 5 years, FCF Margin stood at 17.0% in 2022, then surged by 73 bps to 29.32% in 2023, then fell by 19 bps to 23.85% in 2024, then slipped by 7 bps to 22.28% in 2025, then increased by 29 bps to 28.82% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 28.82% in Q2 2026, 6.09% in Q1 2026, and 22.28% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 43.05% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 2.01% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 25.52% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 29.58% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 26.25% |
| 10 | Jazz Pharmaceuticals | 16.02 Bn | 14.40 Bn | 1.09 Bn | 34.40% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 28.82% |
| Mar 29, 2026 | 6.09% |
| Dec 28, 2025 | 22.28% |
| Sep 28, 2025 | 33.39% |
| Jun 29, 2025 | 11.94% |
| Mar 30, 2025 | 15.43% |
| Dec 29, 2024 | 23.85% |
| Sep 29, 2024 | 30.99% |
| Jun 30, 2024 | 20.75% |
| Mar 31, 2024 | 13.33% |
| Dec 31, 2023 | 29.32% |
| Oct 1, 2023 | 30.55% |
| Jul 2, 2023 | 14.21% |
| Apr 2, 2023 | 11.46% |
| Jan 1, 2023 | 8.75% |
| Apr 3, 2022 | 17.00% |
| Oct 3, 2021 | 32.32% |
| Jul 4, 2021 | 19.31% |
| Apr 4, 2021 | 15.22% |
| Jan 3, 2021 | 31.23% |